Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cells

Abstract Glioblastoma (GBM) is the most common and deadly adult central nervous system cancer. Despite surgical resection combined with DNA-damaging radiation and chemotherapy, GBM almost invariably recurs, becoming more resistant to radiation. To investigate the drivers of this radioresistance, we conducted a knockout radiosensitization screen and identified the High Mobility Group B2 (HMGB2) protein as a potential contributor. To elucidate HMGB2’s role in GBM radioresistance, we performed viability, clonogenic survival, extreme limiting dilution (ELDA), and deletion mutant assays on patient-derived glioblastoma stem cells (GSCs) treated with a combination of radiotherapy (RT) and either HMGB2 knockdown or inhibition using Inflachromene (ICM), a small molecule inhibitor of HMGB2. Without radiation, ICM showed IC-50 values ranging from 8.43 µM to 10 µM across three GSC lines. Both ICM treatment and HMGB2 knockdown significantly reduced neurosphere formation compared to cultures treated with only RT and vehicle. Knockdown of endogenous HMGB2 combined with overexpression of an Acidic Tail-deleted HMGB2 mutant produced distinct puncta under fluorescence microscopy, unlike other deletion mutants. These findings implicate HMGB2 in GBM radioresistance and suggest that the Acidic Tail region mediates chromatin binding, possibly playing a role in HMGB2’s mechanism of action. Together, these results provide a foundation for clarifying HMGB2’s role in GBM biology and it’s potential relevance to improving therapeutic response. Citation Format: Sara Nalina Barcik Weissman, Cheol Park, Connor Mork, Khoi Huynh, Yingwen Ding, Ze-yan Zhang, Eric L. Chang, Erik P. Sulman, Aram S. Modrek. HMGB2-mediated radioresistance of glioblastoma stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7376.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-7376
Primary Topic
Advanced Glycation End Products research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cells

Aram S. Modrek, S. Weissman, Erik P. Sulman, Eric L. Chang et al.
Cancer Research
Advanced Glycation End Products research
article

Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cells

Aram S. Modrek, S. Weissman, Erik P. Sulman, Eric L. Chang, Ze-Yan Zhang, Khoi Huynh, Yingwen Ding, Connor Mork, Cheol Park
article en

Abstract

Abstract Glioblastoma (GBM) is the most common and deadly adult central nervous system cancer. Despite surgical resection combined with DNA-damaging radiation and chemotherapy, GBM almost invariably recurs, becoming more resistant to radiation. To investigate the drivers of this radioresistance, we conducted a knockout radiosensitization screen and identified the High Mobility Group B2 (HMGB2) protein as a potential contributor. To elucidate HMGB2’s role in GBM radioresistance, we performed viability, clonogenic survival, extreme limiting dilution (ELDA), and deletion mutant assays on patient-derived glioblastoma stem cells (GSCs) treated with a combination of radiotherapy (RT) and either HMGB2 knockdown or inhibition using Inflachromene (ICM), a small molecule inhibitor of HMGB2. Without radiation, ICM showed IC-50 values ranging from 8.43 µM to 10 µM across three GSC lines. Both ICM treatment and HMGB2 knockdown significantly reduced neurosphere formation compared to cultures treated with only RT and vehicle. Knockdown of endogenous HMGB2 combined with overexpression of an Acidic Tail-deleted HMGB2 mutant produced distinct puncta under fluorescence microscopy, unlike other deletion mutants. These findings implicate HMGB2 in GBM radioresistance and suggest that the Acidic Tail region mediates chromatin binding, possibly playing a role in HMGB2’s mechanism of action. Together, these results provide a foundation for clarifying HMGB2’s role in GBM biology and it’s potential relevance to improving therapeutic response. Citation Format: Sara Nalina Barcik Weissman, Cheol Park, Connor Mork, Khoi Huynh, Yingwen Ding, Ze-yan Zhang, Eric L. Chang, Erik P. Sulman, Aram S. Modrek. HMGB2-mediated radioresistance of glioblastoma stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7376.

Cancer ResearchVol. 86(7_Supplement)
Keck Hospital of USC (US), New York University (US)
Good health and well-being
Openalex Percentile: Top 4%
Advanced Glycation End Products research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.